Compare · BNR vs CNC
BNR vs CNC
Side-by-side comparison of Burning Rock Biotech Limited (BNR) and Centene Corporation (CNC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNR and CNC operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $45.09B, about 21.9x BNR ($2.06B).
- Over the past year, BNR is up 636.5% and CNC is down 29.8% - BNR leads by 666.3 points.
- CNC has hit the wire 8 times in the past 4 weeks while BNR has been quiet.
- CNC has more recent analyst coverage (25 ratings vs 2 for BNR).
- Company
- Burning Rock Biotech Limited
- Centene Corporation
- Price
- $20.99+1.84%
- $41.83+1.76%
- Market cap
- $2.06B
- $45.09B
- 1M return
- -0.94%
- +27.87%
- 1Y return
- +636.49%
- -29.76%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 8
- Recent ratings
- 2
- 25
Burning Rock Biotech Limited
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass IO, the corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. The company also offers LungCore for lung cancer, ProstrateCore for prostrate cancer, BreastCore for breast cancer, LymphPlasma for lymphomas, and ThyroCare for thyroid cancer. In addition, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone and BeiGene. The company was founded in 2014 and is headquartered in Guangzhou, China.
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Latest BNR
- SEC Form 4 filed by Han Yusheng
- Burning Rock Announces Founder's Purchase of Its ADSs
- SEC Form 3 filed by new insider Deng Feng
- SEC Form 3 filed by new insider Hayes Wendy W.
- New insider Han Yusheng claimed ownership of 17,357,806 units of Ordinary Shares (SEC Form 3)
- New insider Zhang Zhihong claimed ownership of 1,061,990 units of Ordinary Shares (SEC Form 3)
- SEC Form 3 filed by new insider Hu Xiaozhi
- New insider Xu Licen Lisa claimed ownership of 22,718 units of Ordinary Shares (SEC Form 3)
- SEC Form 6-K filed by Burning Rock Biotech Limited
- Burning Rock Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results
Latest CNC
- Centene Foundation Reports $34.9 Million Invested in Community Health, Education and Social Services in 2025
- Superior HealthPlan Employees Contributed More Than 3,000 Volunteer Hours Across Texas Communities in 2025
- Los Angeles Residents to Gain Faster Access to New Affordable Housing through Health Net's $10 Million Investment in "Guarantee Fund"
- Home State Health and Centene Foundation Launch Medical Respite Program in St. Louis
- SEC Form 4 filed by Mcnally Tanya M
- CENTENE CORPORATION TO HOST 2026 FIRST QUARTER FINANCIAL RESULTS EARNINGS CALL
- Sunshine Health Delivers Career Pathways for Floridians and Advances Healthcare Workforce
- Centene Announces New Executive Leadership Structure
- St. Vincent Behavioral Health Campus Expands Housing & Health Care for LA with $6M Health Net Investment
- Carolina Complete Health and WellCare of North Carolina Combine to Form Provider-Led Managed Care Organization